Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Florida
Clinical trial register · United States · industry-sponsored

Clinical Trials in Florida, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9118 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 06 Oct 2026, 03:16 UTC
9118
Studies in scope
industry-sponsored, all four open statuses
4945
Recruiting now
open to new participants
2189
Lead sponsors
across recruiting studies
Top states
California 109 Florida 91 Colorado 71 Georgia 67 Illinois 56
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca174 Eli Lilly and Company150 Merck Sharp & Dohme LLC118 AbbVie112 Novartis Pharmaceuticals110 Clear sponsor filter
State
California109 Florida91 Colorado71 Georgia67 Illinois56
All 42 states
Target enrolment
to

Trials with a site in Florida

91 of 9118 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Study of JNJ-98768111 in Participants With Advanced Prostate Cancer
NCT07746713Prostatic Neoplasms
Janssen Research & Development, LLC
Phase 1
100
Florida, Michigan, Utah
2026-08-05
Recruiting
A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States
NCT07309445Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC
Observational
150
Alabama, Arkansas, California, Colorado, Florida, Illinois, Indiana, Michigan
2026-06-12
Recruiting
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT07518186Multiple Myeloma
DrugsRamantamig·Teclistamab
Janssen Research & Development, LLC
Phase 3
700
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2026-05-31
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07577856Colitis, Ulcerative
DrugsJNJ-78934804·Tremfya·Guselkumab
Janssen Research & Development, LLC
Phase 3
644
California, Colorado, Florida, Georgia, Kentucky, Louisiana, Michigan, New York
2026-05-23
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
NCT07577843Crohn Disease
DrugsJNJ-78934804·Tremfya·Guselkumab
Janssen Research & Development, LLC
Phase 3
460
California, Colorado, Florida, Georgia, Kentucky, Louisiana, Michigan, New York
2026-05-22
Recruiting
A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
NCT07573176Depressive Disorder, Major
DrugSeltorexant
Janssen Research & Development, LLC
Phase 3
600
Arkansas, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Nevada
2026-04-30
Recruiting
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
NCT07499232Crohn Disease
DrugsRisankizumab·Guselkumab
Janssen Research & Development, LLC
Phase 3
530
Alabama, California, Colorado, Connecticut, Florida, Georgia, Iowa, Kansas
2026-04-21
Recruiting
A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer
NCT07524855Metastatic Breast Cancer
Janssen Research & Development, LLC
Phase 1
170
Connecticut, Florida, Massachusetts, Tennessee, Texas, Virginia
2026-04-09
Recruiting
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
NCT07438496Lupus Erythematosus, Systemic
DrugNipocalimab
Janssen Research & Development, LLC
Phase 3
600
California, Colorado, Florida, Georgia, Illinois, Louisiana, Michigan, New Jersey
2026-03-05
Active, closed
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
NCT07266441Multiple Myeloma
DrugRamantamig
Janssen Research & Development, LLC
Phase 2
168
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Iowa
2026-02-08
Recruiting
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
NCT07258511Multiple Myeloma
DrugsRamantamig·Teclistamab
Janssen Research & Development, LLC
Phase 3
400
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2026-02-04
Active, closed
A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis
NCT07230860Dermatitis, Atopic
Janssen Research & Development, LLC
Phase 2
189
California, Florida, Illinois, Indiana, Michigan, North Dakota, Oregon, Pennsylvania
2026-01-20
Recruiting
A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis
NCT07321873Arthritis, Psoriatic
Janssen Research & Development, LLC
Phase 2
240
Arkansas, California, Florida, Georgia, Illinois, Indiana, New Mexico, North Carolina
2026-01-15
Recruiting
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
NCT07319871Prostatic Neoplasms
DrugsJNJ-86974680·Pasritamig
Janssen Research & Development, LLC
Phase 1
40
Florida, New York, Ohio
2026-01-14
Recruiting
Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
NCT07217587Myasthenia Gravis
DrugsEfgartigimod·Nipocalimab
Janssen Research & Development, LLC
Phase 3
115
California, Colorado, Connecticut, Florida, Illinois, Indiana, Louisiana, Massachusetts
2026-01-05
Recruiting
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT07225946Prostatic Neoplasms, Castration-Resistant
DrugsPasritamig·Prednisone/Prednisolone·Docetaxel
Janssen Research & Development, LLC
Phase 3
800
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Kansas
2025-12-19
Recruiting
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
NCT07276399Squamous Cell Carcinoma of Head and Neck
DrugsAmivantamab·Cisplatin·Carboplatin·Pembrolizumab
Janssen Research & Development, LLC
Phase 3
500
Arizona, California, Connecticut, Florida, Georgia, Illinois, Kentucky, Maryland
2025-12-03
Recruiting
A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors
NCT07223125Advanced-stage Solid Tumors
Janssen Research & Development, LLC
Phase 1
360
Florida, Texas
2025-10-10
Recruiting
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
NCT07149857Multiple Myeloma
DrugsCilta-cel·Fludarabine·Cyclophosphamide
Janssen Research & Development, LLC
Phase 2
60
California, Florida, Iowa, New York, North Carolina, Ohio
2025-10-03
Recruiting
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
NCT07196722Crohn Disease
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 2/3
1,092
Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana, Kansas
2025-10-03
Recruiting
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
NCT07196748Colitis, Ulcerative
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
882
Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana, Kansas
2025-10-01
Recruiting
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
NCT06919965Non-Muscle Invasive Bladder Neoplasms
DrugsErdafitinib·Mitomycin C·Gemcitabine
Janssen Research & Development, LLC
Phase 3
220
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Louisiana
2025-09-10
Recruiting
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT07164443Metastatic Castration-resistant Prostatic Neoplasms
DrugsJNJ-87189401·Pasritamig
Janssen Research & Development, LLC
Phase 3
1,203
California, Colorado, Connecticut, District of Columbia, Florida, Iowa, Louisiana, Maryland
2025-09-02
Recruiting
A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors
NCT07107230Advanced Stage Solid Tumors
DrugAmivantamab
Janssen Research & Development, LLC
Phase 1
400
Florida, New York, Tennessee, Virginia
2025-07-15
Recruiting
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
NCT07082920Prostatic Neoplasms
DrugsARX517·JNJ-87189401·Pasritamig
Janssen Research & Development, LLC
Phase 1
140
Florida, New York, Ohio, Washington
2025-07-07
Recruiting
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06852222Leukemia, Myeloid, Acute
DrugsBleximenib·Azacitidine·Venetoclax
Janssen Research & Development, LLC
Phase 3
600
Alabama, Arizona, Arkansas, California, Colorado, Delaware, Florida, Illinois
2025-06-04
Active, closed
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
NCT06934226Plaque Psoriasis
DrugsIcotrokinra·Ustekinumab
Janssen Research & Development, LLC
Phase 3
752
Alabama, California, Connecticut, Florida, Georgia, Illinois, Indiana, Iowa
2025-04-15
Active, closed
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
NCT06878404Arthritis, Psoriatic
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
552
Arkansas, Florida, Illinois, North Carolina, Pennsylvania, Texas
2025-02-21
Recruiting
Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
NCT06800313Metastatic Prostate Cancer
Janssen Research & Development, LLC
Phase 1/2
190
Colorado, Connecticut, Florida, Louisiana, Massachusetts, Michigan, Nebraska, New York
2025-02-06
Recruiting
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
NCT06807424Arthritis, Psoriatic
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
750
Arizona, Arkansas, Florida, Illinois, Maryland, Massachusetts, Minnesota, New Mexico
2025-01-09
Recruiting
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT06667076Carcinoma, Non-Small-Cell Lung
DrugsLazertinib·Amivantamab
Janssen Research & Development, LLC
Phase 2
480
Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida
2024-12-16
Recruiting
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
NCT06750094Colorectal Neoplasms
DrugsLeucovorin calcium/Levoleucovorin·Amivantamab·Erbitux·Avastin
Janssen Research & Development, LLC
Phase 3
700
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2024-12-12
Active, closed
Nipocalimab in Moderate to Severe Sjogren's Disease
NCT06741969Sjogrens Syndrome
DrugNipocalimab
Janssen Research & Development, LLC
Phase 3
655
California, Colorado, Florida, Georgia, Illinois, Iowa, Kansas, Michigan
2024-12-04
Recruiting
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662786Colorectal Neoplasms
DrugsLeucovorin calcium/Levoleucovorin·Amivantamab·Erbitux·Cetuximab
Janssen Research & Development, LLC
Phase 3
1,000
Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2024-10-18
Recruiting
A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
NCT06663319Colorectal Neoplasms, Gastrointestinal Neoplasms
DrugsFolfiri·Folfox·Bevacizumab
Janssen Research & Development, LLC
Phase 1
260
Arizona, Colorado, Florida, Indiana, Michigan, Washington
2024-10-15
Recruiting
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
NCT06635148Geographic Atrophy, Macular Degeneration
Janssen Research & Development, LLC
Phase 2/3
274
Arizona, California, Florida, Georgia, Illinois, Indiana, Maine, Maryland
2024-09-19
Recruiting
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
NCT06559306Depressive Disorder, Major
DrugSeltorexant
Janssen Research & Development, LLC
Phase 3
752
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2024-07-25
Active, closed
A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT06425991Multiple Myeloma
DrugTeclistamab
Janssen Research & Development, LLC
Phase 1
108
Arizona, Colorado, Florida, Georgia, Indiana, Ohio, Texas
2024-06-07
Active, closed
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
NCT05963074Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma
DrugsVenclyxto·Ibrutinib·Venclexta·Venetoclax
Janssen Research & Development, LLC
Phase 2
333
California, Colorado, Florida, Idaho, Illinois, Iowa, Minnesota, Missouri
2024-05-30
Recruiting
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
NCT06319820Non-Muscle Invasive Bladder Neoplasms
DrugGemcitabine
Janssen Research & Development, LLC
Phase 3
641
Arkansas, California, Colorado, Florida, Illinois, Indiana, Kansas, Louisiana
2024-04-18
Active, closed
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
NCT06211764Non-Muscle Invasive Bladder Neoplasms
DrugsTAR-200·Mitomycin C·Gemcitabine
Janssen Research & Development, LLC
Phase 3
272
Arkansas, California, Colorado, Florida, Illinois, Indiana, Kansas, Michigan
2024-04-09
Active, closed
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
NCT06220604Plaque Psoriasis
DrugsIcotrokinra·Deucravacitinib
Janssen Research & Development, LLC
Phase 3
731
Arizona, California, Florida, Georgia, Illinois, Kentucky, Maryland, Massachusetts
2024-03-09
Active, closed
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
NCT06208150Multiple Myeloma
DrugsElotuzumab·Talquetamab·Velcade·Teclistamab
Janssen Research & Development, LLC
Phase 3
838
California, Connecticut, Delaware, Florida, Georgia, Idaho, Illinois, Iowa
2024-01-22
Active, closed
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
NCT06143878Plaque Psoriasis
DrugsIcotrokinra·Deucravacitinib
Janssen Research & Development, LLC
Phase 3
774
Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana, Kentucky
2024-01-17
Recruiting
A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
NCT05912517Hemolytic Disease of the Fetus and Newborn
DrugNipocalimab
Janssen Research & Development, LLC
Phase 3
120
California, Colorado, Florida, Illinois, Indiana, Iowa, Kentucky, Maryland
2023-12-20
Recruiting
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
NCT06150157Neoplasms
DrugsMomelotinib·Ruxolitinib
Janssen Research & Development, LLC
Phase 1
300
California, Colorado, Florida, Georgia, Michigan, New Jersey, New York, North Carolina
2023-12-20
Active, closed
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
NCT06095115Plaque Psoriasis
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
684
Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana, Kentucky
2023-10-12
Active, closed
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
NCT06095102Plaque Psoriasis
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
311
Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana, Louisiana
2023-10-12
Active, closed
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC
NCT05884398Metastatic Castrate-sensitive Prostate Cancer
DrugApalutamide
Janssen Research & Development, LLC
Phase 3
420
Alabama, Arizona, Arkansas, California, Colorado, Florida, Illinois, Indiana
2023-08-31
Recruiting
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
NCT05818683Metastatic Castration-resistant Prostate Neoplasms, Metastatic Hormone-sensitive Prostate Cancer
DrugsJNJ-101556143·Lutetium Lu-177 vipivotide tetraxetan·Pasritamig·Cabazitaxel
Janssen Research & Development, LLC
Phase 1
300
Florida, Michigan, Missouri, New York, Pennsylvania
2023-04-26
Active, closed
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05572515Relapsed or Refractory Multiple Myeloma
DrugsTeclistamab·Carfilzomib·Pomalidomide·Bortezomib
Janssen Research & Development, LLC
Phase 3
614
Alaska, Arizona, California, Colorado, Connecticut, Florida, Iowa, Louisiana
2023-03-29
Active, closed
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
NCT05714202Bladder Cancer
DrugsTAR-200·Cetrelimab
Janssen Research & Development, LLC
Phase 3
1,135
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Indiana
2023-03-23
Active, closed
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034Ischemic Stroke; Ischemic Attack, Transient
DrugMilvexian
Janssen Research & Development, LLC
Phase 3
12,523
Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2023-02-15
Active, closed
A Study of Daratumumab
NCT05438043Multiple Myeloma
DrugsCarfilzomib·Pomalidomide·Daratumumab·Lenalidomide
Janssen Research & Development, LLC
Phase 3
213
Florida, Georgia, Michigan, Missouri, New York, Texas
2022-12-15
Recruiting
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
NCT05498428Carcinoma, Non-small-Cell Lung
DrugsDirect Anticoagulant·LMWH·DOAC·Low molecular weight heparin
Janssen Research & Development, LLC
Phase 2
520
California, District of Columbia, Florida, Kansas, Maryland, Massachusetts, Missouri, New Jersey
2022-11-11
Recruiting
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
NCT05552222Multiple Myeloma
DrugsTalquetamab·Teclistamab·Daratumumab·Lenalidomide
Janssen Research & Development, LLC
Phase 3
1,590
Arizona, California, Connecticut, Delaware, Florida, Georgia, Illinois, Iowa
2022-10-25
Active, closed
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
NCT05455320Multiple Myeloma
DrugsTalquetamab·Pomalidomide·Daratumumab·Dexamethasone
Janssen Research & Development, LLC
Phase 3
864
Arizona, Arkansas, Connecticut, District of Columbia, Florida, Illinois, Kansas, Louisiana
2022-10-13
Recruiting
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT05327114Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
DrugNipocalimab
Janssen Research & Development, LLC
Phase 2/3
201
Colorado, Florida, Georgia, Kansas, Maryland, Massachusetts, Michigan, Missouri
2022-09-23
Active, closed
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05242484Colitis, Ulcerative
DrugsJNJ-78934804·Golimumab·Guselkumab
Janssen Research & Development, LLC
Phase 2
577
California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana
2022-09-19
Active, closed
A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05528510Colitis, Ulcerative
DrugsGuselkumab 1·Guselkumab 2·Guselkumab 3
Janssen Research & Development, LLC
Phase 3
418
Arizona, California, Colorado, Florida, Georgia, Kansas, Michigan, New York
2022-09-13
Active, closed
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
NCT05388669Advanced or Metastatic Non-small Cell Lung Cancer
DrugsLazertinib·Amivantamab
Janssen Research & Development, LLC
Phase 3
418
California, Colorado, Florida, Kansas, Michigan, New Jersey, New York, Oregon
2022-08-05
Recruiting
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
NCT05379595Advanced or Metastatic Colorectal Cancer
DrugsAmivantamab·Fluorouracil·Leucovorin·Irinotecan
Janssen Research & Development, LLC
Phase 1/2
225
Alabama, California, District of Columbia, Florida, Maryland, Michigan, Mississippi, New York
2022-07-29
Active, closed
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
NCT05242471Crohn's Disease
DrugsJNJ-78934804·Golimumab·Guselkumab
Janssen Research & Development, LLC
Phase 2
703
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2022-07-22
Recruiting
A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
NCT05265273Myasthenia Gravis
DrugNipocalimab
Janssen Research & Development, LLC
Phase 2/3
12
Arizona, California, Colorado, Florida, Kansas, Michigan, Pennsylvania
2022-07-20
Active, closed
A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies
NCT05379634Myositis
DrugNipocalimab
Janssen Research & Development, LLC
Phase 2
36
Arizona, California, Florida, Georgia, Kansas, Maryland, Massachusetts, Michigan
2022-07-05
Active, closed
Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
NCT05316155Non-Muscle Invasive Bladder Neoplasms
DrugErdafitinib
Janssen Research & Development, LLC
Phase 1/2
235
Alabama, California, Colorado, Florida, Illinois, Indiana, Kentucky, Louisiana
2022-04-11
Recruiting
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
NCT05201781Multiple Myeloma
DrugCilta-cel
Janssen Research & Development, LLC
Phase 4
295
Arizona, California, Florida, Georgia, Illinois, Indiana, Kansas, Massachusetts
2022-03-09
Active, closed
A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis
NCT05250973Amyloidosis
DrugsBortezomib·Daratumumab·Dexamethasone·Cyclophosphamide
Janssen Research & Development, LLC
Phase 2
151
California, Connecticut, Florida, Georgia, Massachusetts, Michigan, New York, North Carolina
2022-03-01
Active, closed
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease
NCT05197049Crohn Disease
DrugsGuselkumab 1·Guselkumab 2·Guselkumab 3
Janssen Research & Development, LLC
Phase 3
350
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2022-01-19
Active, closed
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
NCT04988295Carcinoma, Non-Small-Cell Lung
DrugsLazertinib·Amivantamab·Pemetrexed·Carboplatin
Janssen Research & Development, LLC
Phase 3
776
Alabama, Arizona, California, Colorado, Florida, Georgia, Mississippi, Nebraska
2021-11-17
Active, closed
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
NCT04929210Arthritis, Psoriatic
DrugsTremfya·Guselkumab
Janssen Research & Development, LLC
Phase 4
411
Arizona, Arkansas, California, Connecticut, Florida, Illinois, Maryland, Michigan
2021-08-30
Active, closed
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
NCT04923893Multiple Myeloma
DrugsCilta-cel·Bortezomib·Lenalidomide·Fludarabine
Janssen Research & Development, LLC
Phase 3
743
California, Connecticut, Florida, Iowa, Kentucky, Maryland, Massachusetts, Michigan
2021-08-19
Recruiting
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
NCT04951622Myasthenia Gravis
DrugNipocalimab
Janssen Research & Development, LLC
Phase 3
199
Arizona, California, Colorado, Connecticut, Florida, Georgia, Kansas, Massachusetts
2021-07-15
Active, closed
A Study of Guselkumab in Participants With Active Psoriatic Arthritis
NCT04882098Arthritis, Psoriatic
DrugGuselkumab
Janssen Research & Development, LLC
Phase 3
1,054
Alabama, Arizona, California, Florida, Maryland, Michigan, Missouri, Montana
2021-06-17
Recruiting
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04634552Hematological Malignancies
DrugTalquetamab
Janssen Research & Development, LLC
Phase 2
510
Alabama, Arkansas, California, Florida, Georgia, Illinois, Kentucky, Michigan
2021-02-01
Active, closed
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
NCT04658862Urinary Bladder Neoplasms
DrugsTAR-200·Cetrelimab·Gemcitabine·Cisplatin
Janssen Research & Development, LLC
Phase 3
518
California, Colorado, Florida, Georgia, Illinois, Michigan, Nebraska, New Jersey
2020-12-07
Active, closed
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
NCT04644770Prostatic Neoplasms, Adenocarcinoma
DrugPasritamig
Janssen Research & Development, LLC
Phase 1
144
Arizona, California, Florida, Illinois, Louisiana, Minnesota, Nebraska, New York
2020-11-12
Active, closed
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
NCT04538664Carcinoma, Non-Small-Cell Lung
DrugsAmivantamab·Pemetrexed·Carboplatin
Janssen Research & Development, LLC
Phase 3
308
California, District of Columbia, Florida, Georgia, Michigan, Missouri, New Jersey, New York
2020-10-13
Active, closed
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT04487080Carcinoma, Non-Small-Cell Lung
DrugsLazertinib·Amivantamab·Osimertinib
Janssen Research & Development, LLC
Phase 3
1,074
Arizona, California, Colorado, Florida, Georgia, Louisiana, Maryland, Michigan
2020-09-30
Active, closed
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)
NCT04497844Prostatic Neoplasms
DrugsAbiraterone acetate·Prednisone
Janssen Research & Development, LLC
Phase 3
696
Alabama, Arizona, California, Colorado, Connecticut, Florida, Indiana, Louisiana
2020-09-23
Active, closed
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
NCT04181827Multiple Myeloma
DrugsCilta-cel·Pomalidomide·Bortezomib·Daratumumab
Janssen Research & Development, LLC
Phase 3
419
Alabama, Arizona, California, Colorado, Connecticut, Florida, Iowa, Kansas
2020-06-12
Active, closed
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
NCT04133636Multiple Myeloma
DrugsCilta-cel·Bortezomib·Daratumumab·Lenalidomide
Janssen Research & Development, LLC
Phase 2
208
California, Connecticut, Florida, Georgia, Illinois, Indiana, Iowa, Kansas
2019-11-07
Active, closed
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT04033445Ulcerative Colitis
DrugGuselkumab
Janssen Research & Development, LLC
Phase 2/3
1,064
California, Colorado, Florida, Georgia, Illinois, Kansas, Kentucky, Massachusetts
2019-09-26
Active, closed
A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer
NCT04077463Carcinoma, Non-Small-Cell Lung
DrugsLazertinib·Amivantamab·Pemetrexed·Carboplatin
Janssen Research & Development, LLC
Phase 1
701
California, Florida, Massachusetts, Michigan, Missouri, New York, Oregon, Pennsylvania
2019-09-04
Active, closed
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia
NCT04119050Warm Autoimmune Hemolytic Anemia
DrugNipocalimab
Janssen Research & Development, LLC
Phase 2/3
118
California, Colorado, Florida, Illinois, Kansas, Louisiana, Michigan, Missouri
2019-08-15
Active, closed
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
NCT03767244Prostatic Neoplasms
DrugApalutamide
Janssen Research & Development, LLC
Phase 3
2,517
California, Colorado, Connecticut, Florida, Georgia, Illinois, Louisiana, Massachusetts
2019-06-11
Active, closed
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
NCT03748641Castration-Resistant Prostatic Cancer
DrugsAbiraterone acetate·Niraparib·Prednisone
Janssen Research & Development, LLC
Phase 3
765
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Illinois
2019-01-25
Active, closed
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
NCT03466411Crohn's Disease
DrugsGuselkumab 1·Guselkumab 2·Guselkumab 3·Ustekinumab
Janssen Research & Development, LLC
Phase 2/3
1,409
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2018-04-13
Active, closed
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
NCT03390504Urothelial Cancer
DrugsVinflunine·Erdafitinib·Docetaxel·Pembrolizumab
Janssen Research & Development, LLC
Phase 3
629
Alaska, California, District of Columbia, Florida, Georgia, Illinois, Kentucky, Maryland
2018-03-23
Active, closed
A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
NCT03431350Prostatic Neoplasms, Castration-Resistant
DrugsCetrelimab·Abiraterone acetate·Niraparib·Prednisone
Janssen Research & Development, LLC
Phase 2
136
Arizona, Colorado, Florida, Indiana, Maryland, Michigan, New York, Pennsylvania
2018-03-02
Active, closed
Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer
NCT02609776Non-Small-Cell Lung Cancer
DrugsLazertinib·Amivantamab·Pemetrexed·Carboplatin
Janssen Research & Development, LLC
Phase 1
751
California, Florida, Illinois, Maryland, Massachusetts, Michigan, Minnesota, Missouri
2016-05-24
Rows per page Showing 1–91 of 91
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 7 October 2026. https://priyalifescience.com/clinical-trials-usa/state/florida

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,118 studies in total at the last sync on 06 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 91 of those studies with a site in Florida that also match the filters currently applied.

How many clinical trials are recruiting in Florida?

44 of the 91 studies on this page are recruiting new participants as of the 06 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 47 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Florida), 91 studies
PhaseStudiesRecruitingShare
Phase 3512256%
Phase 214515.4%
Phase 113914.3%
Phase 2/3747.7%
Phase 1/2323.3%
Phase 4212.2%
Observational111.1%

Most active sponsors

Lead sponsors with the most studies (Florida)
Lead sponsorStudiesRecruiting
Janssen Research & Development, LLC9144
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.